Toblli, J. E., & Di Gennaro, F. (2015). Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: Effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. Web
Citación estilo ChicagoToblli, Jorge Eduardo, and Federico Di Gennaro. Switching Patients With Non-dialysis Chronic Kidney Disease From Oral Iron to Intravenous Ferric Carboxymaltose: Effects On Erythropoiesis-stimulating Agent Requirements, Costs, Hemoglobin and Iron Status. 2015.
Cita MLAToblli, Jorge Eduardo, and Federico Di Gennaro. Switching Patients With Non-dialysis Chronic Kidney Disease From Oral Iron to Intravenous Ferric Carboxymaltose: Effects On Erythropoiesis-stimulating Agent Requirements, Costs, Hemoglobin and Iron Status. 2015.